Mechanisms of Drug Resistance in Cancer Therapy
Toxicology Oncology Drug interactions Medicine Pharmacology/Toxicology Cancer Research Drug Resistance Molecular Medicine
Imprint: Springer
2018
1st ed. 2018.
EISBN 3030105075
1. Molecular and Pharmacological Mechanisms of Drug Resistance: An Evolving Paradigm.
2. Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival.
3. Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.
4. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
5. Mechanisms of Drug Resistance in Melanoma.
6. Mechanisms of Resistance to Immune Checkpoint Antibodies.
7. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
8. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
9. Targeting DNA repair.
10. Resistance to Hormonal Therapy in Prostate Cancer.
11. Mechanism of Resistance in Gastrointestinal Stromal Tumors.
12. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.
13. Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.
14. Mechanisms of Resistance in Multiple Myeloma.
15. Cancer Evolution as the New Frontier of Precision.
A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.
2. Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival.
3. Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.
4. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
5. Mechanisms of Drug Resistance in Melanoma.
6. Mechanisms of Resistance to Immune Checkpoint Antibodies.
7. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
8. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
9. Targeting DNA repair.
10. Resistance to Hormonal Therapy in Prostate Cancer.
11. Mechanism of Resistance in Gastrointestinal Stromal Tumors.
12. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.
13. Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.
14. Mechanisms of Resistance in Multiple Myeloma.
15. Cancer Evolution as the New Frontier of Precision.
A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.
